JP5649577B2 - ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法 - Google Patents

ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法 Download PDF

Info

Publication number
JP5649577B2
JP5649577B2 JP2011527709A JP2011527709A JP5649577B2 JP 5649577 B2 JP5649577 B2 JP 5649577B2 JP 2011527709 A JP2011527709 A JP 2011527709A JP 2011527709 A JP2011527709 A JP 2011527709A JP 5649577 B2 JP5649577 B2 JP 5649577B2
Authority
JP
Japan
Prior art keywords
general formula
group
reaction
compound represented
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011527709A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2011021676A1 (ja
Inventor
久元 辻森
久元 辻森
伸一 平良
伸一 平良
浩孝 湯川
浩孝 湯川
薫 阿部
薫 阿部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JPWO2011021676A1 publication Critical patent/JPWO2011021676A1/ja
Application granted granted Critical
Publication of JP5649577B2 publication Critical patent/JP5649577B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011527709A 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法 Expired - Fee Related JP5649577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23598809P 2009-08-21 2009-08-21
US61/235988 2009-08-21
PCT/JP2010/064040 WO2011021676A1 (ja) 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法

Publications (2)

Publication Number Publication Date
JPWO2011021676A1 JPWO2011021676A1 (ja) 2013-01-24
JP5649577B2 true JP5649577B2 (ja) 2015-01-07

Family

ID=43607124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527709A Expired - Fee Related JP5649577B2 (ja) 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法

Country Status (11)

Country Link
US (2) US8796447B2 (OSRAM)
EP (1) EP2468733A4 (OSRAM)
JP (1) JP5649577B2 (OSRAM)
KR (1) KR20120065360A (OSRAM)
CN (1) CN102639512B (OSRAM)
BR (1) BR112012003871A2 (OSRAM)
CA (1) CA2771136A1 (OSRAM)
IL (1) IL217855A (OSRAM)
IN (1) IN2012DN00986A (OSRAM)
RU (1) RU2553676C2 (OSRAM)
WO (1) WO2011021676A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404984A (zh) 2022-04-28 2024-02-01 日商第一三共股份有限公司 苯并三唑化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1005A (en) * 1838-11-12 Ing and heating booms and other apabtments beqtjibing abtrficial
US3133056A (en) 1961-05-15 1964-05-12 May & Baker Ltd N-phenylpiperazine derivatives of tetrahydrobenzodiazepines
US4001408A (en) * 1966-12-14 1977-01-04 Roussel-Uclaf Substituted heterocyclic compounds, processes and composition including those
US3984398A (en) 1966-12-14 1976-10-05 Roussel-Uclaf 1,5-Benzodiazepine-2,4-diones
BE707667A (OSRAM) * 1966-12-14 1968-06-07
SU455539A3 (ru) * 1970-11-02 1974-12-30 К.Х.Берингре Зон (Фирма) Способ получени 2-алкокси-5 фенил-4н-3,5-дигидро-1,5-бензодиазепин-4-онов
GB1460936A (en) 1974-10-01 1977-01-06 Beecham Group Ltd Benzodiazepines
IE46852B1 (en) 1977-06-10 1983-10-05 Otsuka Pharma Co Ltd Novel carbostyril derivatives
JPS56122356A (en) 1980-02-29 1981-09-25 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JP2753622B2 (ja) 1988-05-02 1998-05-20 大塚製薬株式会社 カルボスチリル誘導体
JPH0296133A (ja) 1988-10-01 1990-04-06 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
BR9200951A (pt) 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
AU653060B2 (en) 1991-08-23 1994-09-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative and platelet agglutination inhibitor
PE27497A1 (es) 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
US5691331A (en) 1995-06-07 1997-11-25 Merck & Co., Inc. N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides
US5700797A (en) 1995-06-07 1997-12-23 Merck & Co, Inc. N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
TW338037B (en) 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
GB0008179D0 (en) * 2000-04-05 2000-05-24 Glaxo Group Ltd Chemical process
AU6895000A (en) 1999-08-09 2001-03-05 Merck & Co., Inc. Antiarrhythmic compounds
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
EP2254873B1 (en) 2008-02-22 2014-06-04 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
TWI481601B (zh) * 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物

Also Published As

Publication number Publication date
IN2012DN00986A (OSRAM) 2015-04-10
CN102639512A (zh) 2012-08-15
IL217855A0 (en) 2012-03-29
BR112012003871A2 (pt) 2015-09-08
CN102639512B (zh) 2015-12-09
EP2468733A4 (en) 2013-02-06
CA2771136A1 (en) 2011-02-24
KR20120065360A (ko) 2012-06-20
EP2468733A1 (en) 2012-06-27
US20120149899A1 (en) 2012-06-14
IL217855A (en) 2016-08-31
US8796447B2 (en) 2014-08-05
RU2012110566A (ru) 2013-09-27
WO2011021676A1 (ja) 2011-02-24
RU2553676C2 (ru) 2015-06-20
US20140194621A1 (en) 2014-07-10
US8940889B2 (en) 2015-01-27
JPWO2011021676A1 (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
US7601837B2 (en) Quinoline derivatives and their use as 5-HT6 ligands
EP1221440B1 (en) Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
US4935420A (en) Benzoheterocyclic compounds
EP1988777B1 (en) Pyrazoles for the treatment of obesity and other cns disorders
US9856215B2 (en) Preparation method of Nintedanib
CZ285492A3 (en) Benzanilide derivatives, process of their preparation and pharmaceutical compositions in which they are comprised
US8362056B2 (en) 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
HU195961B (en) Process for producing substituted 2-/1h/-quinolone derivatives
IT8149084A1 (it) Composti eterociclici indolici, procedimento per produrli e composizioni farmaceutiche che li contengono
Stadlbauer et al. Halogenation reactions in position 3 of quinoline-2, 4-dione systems by electrophilic substitution and halogen exchange
US5798353A (en) Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them
US5416221A (en) Carbazolone derivatives
HU189747B (en) Process for producing 1-phenyl-2/1h,3h/-indolone derivatives and pharmaceutical compositions containing them
JP2009512635A (ja) Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5649577B2 (ja) ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法
US6353103B1 (en) Isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
US4767756A (en) 3-substituted benzazepines
AU2009221091B2 (en) Process for preparing enantiomerically pure indolopyridines
JPS61286367A (ja) ベンズアゼピン誘導体
US7126009B2 (en) Palladium catalyzed indolization of 2-bromo or chloroanilines
US4771047A (en) Benzazepine derivatives
US4824831A (en) 4,5-dihydro-1H-benzazepine-3-carboxylic acid esters which are useful as anti-hypertensive agents
TWI300409B (en) Method for producing 4-nitroimidazole compound
JP4975817B2 (ja) アリールピペラジン誘導体およびその使用
TW201418197A (zh) 合成（２ｅ）－３－（３，４－二甲氧基苯基）丙－２－烯腈之新穎方法及於合成伊伐布雷定（ｉｖａｂｒａｄｉｎｅ）及其與醫藥上可接受之酸的加成鹽之應用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141111

R150 Certificate of patent or registration of utility model

Ref document number: 5649577

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees